title: Rapid emergence of resistance to linezolid and mutator phenotypes in Staphylococcus aureus isolates from an adult cystic fibrosis patient.
abstract: Linezolid has emerged as an important therapeutic option for the treatment of Staphylococcus aureus in patients with cystic fibrosis. We report the rapid emergence, upon treatment with linezolid, of linezolid-resistant S. aureus clinical isolates through the accumulation of resistance-associated 23S rRNA mutations, together with acquisition of an altered mutator phenotype.
authors.affiliation: Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, Paris, France.
authors.forename: Asmaa
authors.initials: A
authors.lastname: Tazi
authors.forename: Jeanne
authors.initials: J
authors.lastname: Chapron
authors.forename: Gerald
authors.initials: G
authors.lastname: Touak
authors.forename: Magalie
authors.initials: M
authors.lastname: Longo
authors.forename: Dominique
authors.initials: D
authors.lastname: Hubert
authors.forename: Gislène
authors.initials: G
authors.lastname: Collobert
authors.forename: Daniel
authors.initials: D
authors.lastname: Dusser
authors.forename: Claire
authors.initials: C
authors.lastname: Poyart
authors.forename: Philippe C
authors.initials: PC
authors.lastname: Morand
mesh_terms: D000081:Acetamides; D000328:Adult; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D003550:Cystic Fibrosis / Q000188:drug therapy / Q000235:genetics / Q000382:microbiology*; D006801:Humans; D000069349:Linezolid; D023303:Oxazolidinones; D012338:RNA, Ribosomal, 23S / Q000235:genetics; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000235:genetics / Q000472:pathogenicity
chemical_list: D000081:Acetamides; D000900:Anti-Bacterial Agents; D023303:Oxazolidinones; D012338:RNA, Ribosomal, 23S; D000069349:Linezolid
references.citation: J Infect Dis. 2002 Dec 1;186(11):1603-7
references.pmid: 12447736
references.citation: Antimicrob Agents Chemother. 2008 Apr;52(4):1570-2
references.pmid: 18212098
references.citation: Clin Pharmacokinet. 2010 Jul;49(7):439-47
references.pmid: 20528004
references.citation: Mol Microbiol. 2007 Jun;64(6):1506-14
references.pmid: 17555436
references.citation: J Bacteriol. 2005 May;187(10):3455-64
references.pmid: 15866932
references.citation: J Antimicrob Chemother. 2004 Oct;54(4):818-20
references.pmid: 15347637
references.citation: J Clin Microbiol. 1995 Mar;33(3):551-5
references.pmid: 7751356
references.citation: Antimicrob Agents Chemother. 2009 Dec;53(12):5265-74
references.pmid: 19752277
references.citation: J Antimicrob Chemother. 2013 Jan;68(1):4-11
references.pmid: 22949625
references.citation: Antimicrob Agents Chemother. 2011 Apr;55(4):1684-92
references.pmid: 21263048
references.citation: J Antimicrob Chemother. 2004 Feb;53(2):325-8
references.pmid: 14729733
references.citation: J Antimicrob Chemother. 2010 Mar;65(3):442-5
references.pmid: 20089543
references.citation: Lancet. 2001 Jul 21;358(9277):207-8
references.pmid: 11476839
references.citation: Int J Med Microbiol. 2012 Jul;302(3):145-7
references.pmid: 22578666
references.citation: Antimicrob Agents Chemother. 2004 Jan;48(1):281-4
references.pmid: 14693551
references.citation: Antimicrob Agents Chemother. 2010 Apr;54(4):1443-52
references.pmid: 20100878
references.citation: FEMS Immunol Med Microbiol. 2007 Nov;51(2):344-9
references.pmid: 17714489
references.citation: J Infect Dis. 2003 Jun 1;187(11):1709-16
references.pmid: 12751028
references.citation: Antimicrob Agents Chemother. 2011 Jul;55(7):3393-8
references.pmid: 21518837
references.citation: Clin Microbiol Infect. 2010 Jul;16(7):798-808
references.pmid: 20880409
references.citation: Antimicrob Agents Chemother. 2002 Apr;46(4):1080-5
references.pmid: 11897593
references.citation: J Antimicrob Chemother. 2003 Jan;51(1):186-8
references.pmid: 12493812